Aysooda Hosseinzadeh
Overview
Explore the profile of Aysooda Hosseinzadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shokrollahi Barough M, Jalili N, Shafiee S, Salehi M, Naseri N, Javidi M, et al.
Int Immunopharmacol
. 2023 Aug;
124(Pt A):110792.
PMID: 37633239
Introduction: One of the most pressing concerns associated with breast cancer-targeted therapies is resistance to Tamoxifen and Herceptin. Such drug resistance is usually characterized by reduced expression of certain cell...
2.
Hosseinzadeh A, Poursoleiman F, Biregani A, Esmailzadeh A
Cancer Cell Int
. 2023 Jun;
23(1):114.
PMID: 37308913
Despite the success of cancer therapy, it has encountered a major obstacle due to the complicated nature of cancer, namely resistance. The recurrence and metastasis of cancer occur when anti-cancer...
3.
Barzaman K, Vafaei R, Samadi M, Kazemi M, Hosseinzadeh A, Merikhian P, et al.
Cancer Cell Int
. 2022 Aug;
22(1):259.
PMID: 35986321
As an intelligent disease, tumors apply several pathways to evade the immune system. It can use alternative routes to bypass intracellular signaling pathways, such as nuclear factor-κB (NF-κB), Wnt, and...
4.
Hosseinzadeh A, Merikhian P, Naseri N, Eisavand M, Farahmand L
Cancer Cell Int
. 2022 Mar;
22(1):110.
PMID: 35248049
Although resistance is its major obstacle in cancer therapy, trastuzumab is the most successful agent in treating epidermal growth factor receptor 2 positive (HER2 +) breast cancer (BC). Some patients...
5.
Vafaei R, Samadi M, Hosseinzadeh A, Barzaman K, Esmailinejad M, Khaki Z, et al.
Cancer Cell Int
. 2022 Jan;
22(1):14.
PMID: 35000604
Mucin-1 (MUC-1) is a transmembrane glycoprotein, which bears many similarities between dogs and humans. Since the existence of animal models is essential to understand the significant factors involved in breast...
6.
Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, Kazemi M, Khorramdelazad H, Safari E, et al.
Int Immunopharmacol
. 2021 Jun;
98:107886.
PMID: 34153663
The crucial role of the immune system in the progression/regression of breast cancer (BC) should always be taken into account. Various immunotherapy approaches have been investigated for BC, including tumor-targeting...
7.
Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi M, Moradi-Kalbolandi S, et al.
Int Immunopharmacol
. 2020 May;
84:106535.
PMID: 32361569
During the past recent years, various therapies emerged in the era of breast cancer. Breast cancer is a heterogeneous disease in which genetic and environmental factors are involved. Breast cancer...